Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $6.67 Average Target Price from Brokerages

Gossamer Bio, Inc. (NASDAQ:GOSS) has been assigned an average rating of “Hold” from the ten research firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $5.4286.

A number of equities research analysts have recently issued reports on the stock. Oppenheimer reduced their price target on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating for the company in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd. Barclays cut Gossamer Bio from an “overweight” rating to an “underweight” rating in a report on Tuesday, February 24th. Royal Bank Of Canada upgraded Gossamer Bio to an “outperform” rating in a research report on Tuesday, February 24th. Finally, The Goldman Sachs Group lowered Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th.

Gossamer Bio Stock Down 4.0%

Shares of NASDAQ GOSS opened at $0.50 on Wednesday. The stock has a market capitalization of $115.89 million, a price-to-earnings ratio of -0.73 and a beta of 2.08. Gossamer Bio has a 52 week low of $0.33 and a 52 week high of $3.87. The firm has a 50-day moving average price of $2.12 and a 200 day moving average price of $2.57.

Institutional Investors Weigh In On Gossamer Bio

A number of large investors have recently bought and sold shares of the stock. MB Generational Wealth LLC acquired a new stake in shares of Gossamer Bio during the 3rd quarter worth about $3,721,000. Corient Private Wealth LLC grew its holdings in shares of Gossamer Bio by 8.9% during the second quarter. Corient Private Wealth LLC now owns 3,693,683 shares of the company’s stock worth $4,543,000 after buying an additional 302,200 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Gossamer Bio by 12.4% in the second quarter. Acadian Asset Management LLC now owns 7,146,022 shares of the company’s stock valued at $8,786,000 after buying an additional 787,909 shares during the last quarter. ProShare Advisors LLC acquired a new position in shares of Gossamer Bio in the second quarter valued at approximately $48,000. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Gossamer Bio during the second quarter valued at approximately $53,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.